ID

27815

Description

Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00558493

Lien

https://clinicaltrials.gov/show/NCT00558493

Mots-clés

Versions (1)
  1. 30/11/2017 30/11/2017 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

30 novembre 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Chronic Hepatitis B NCT00558493

Anglais

Eligibility Chronic Hepatitis B NCT00558493

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
hbv dna > 2,000 copies/ml at screening
Description

Hepatitis B DNA Measurement

Type de données

boolean

Alias
UMLS CUI [1]
C3641250
patients who have compensated liver disease (child-pugh score =<6)
Description

Compensated liver disease Child-Pugh - Total Score

Type de données

boolean

Alias
UMLS CUI [1,1]
C3839044
UMLS CUI [1,2]
C4055253
patients without lmv resistant mutation by rfmp assay
Description

Absence Mutation Lamivudine Resistant | Other Coding

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C0026882
UMLS CUI [1,3]
C0209738
UMLS CUI [1,4]
C0332325
UMLS CUI [2]
C3846158
patients who have not experienced viral breakthrough at consecutive two measurements (at least one month apart) during lamivudine monotherapy
Description

Viral Breakthrough Absent Measurement Quantity | Lamivudine

Type de données

boolean

Alias
UMLS CUI [1,1]
C4053869
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C0242485
UMLS CUI [1,4]
C1265611
UMLS CUI [2]
C0209738
patients who can submit the written consent and comply with the claims postulated of this clinical trial
Description

Informed Consent | Protocol Compliance

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2]
C0525058
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
currently receiving antiviral except lmv or corticosteroid therapy
Description

Antiviral Therapy | Exception Lamivudine | Exception Steroid therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0280274
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0209738
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0149783
patients that previously received antiviral treatment for hepatitis b other than lamivudine in the proceeding 12 months
Description

Antiviral Therapy Hepatitis B | Exception Lamivudine

Type de données

boolean

Alias
UMLS CUI [1,1]
C0280274
UMLS CUI [1,2]
C0019163
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0209738
previous treatment with interferon or other immunomodulatory therapies must have ended at least 6 months preceding the study screening
Description

Interferon To be stopped | Immunomodulation To be stopped

Type de données

boolean

Alias
UMLS CUI [1,1]
C3652465
UMLS CUI [1,2]
C1272691
UMLS CUI [2,1]
C1963758
UMLS CUI [2,2]
C1272691
treatment with nephrotoxic drugs, competitors of renal excretion, and/or hepatotoxic drugs within 2 months before study screening or during the study period
Description

Pharmaceutical Preparations Nephrotoxic | Pharmaceutical Preparations Hepatotoxicity

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1514118
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0235378
patients who is co-infected with hcv, hdv or hiv
Description

HCV coinfection | HDV Coinfection | HIV coinfection

Type de données

boolean

Alias
UMLS CUI [1]
C1698259
UMLS CUI [2,1]
C0011220
UMLS CUI [2,2]
C0275524
UMLS CUI [3]
C4062778
serious concurrent medical conditions
Description

Other medical condition Serious

Type de données

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0205404
prior organ transplantation
Description

Organ Transplantation

Type de données

boolean

Alias
UMLS CUI [1]
C0029216
patient has creatinine clearance less than 60ml/min as estimated by the following formula:
Description

Estimation of creatinine clearance by Cockcroft-Gault formula

Type de données

boolean

Alias
UMLS CUI [1]
C2711451
[(140-age in years) (body weight [kg])] / [(72) (serum creatinine] [mg/dl])[note: multiply estimates by 0.85 for women]
Description

Estimation of creatinine clearance by Cockcroft-Gault formula | Gender

Type de données

boolean

Alias
UMLS CUI [1]
C2711451
UMLS CUI [2]
C0079399
Retour au début de la page

Similar models

Eligibility Chronic Hepatitis B NCT00558493

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Hepatitis B DNA Measurement
Item
hbv dna > 2,000 copies/ml at screening
boolean
C3641250 (UMLS CUI [1])
Compensated liver disease Child-Pugh - Total Score
Item
patients who have compensated liver disease (child-pugh score =<6)
boolean
C3839044 (UMLS CUI [1,1])
C4055253 (UMLS CUI [1,2])
Absence Mutation Lamivudine Resistant | Other Coding
Item
patients without lmv resistant mutation by rfmp assay
boolean
C0332197 (UMLS CUI [1,1])
C0026882 (UMLS CUI [1,2])
C0209738 (UMLS CUI [1,3])
C0332325 (UMLS CUI [1,4])
C3846158 (UMLS CUI [2])
Viral Breakthrough Absent Measurement Quantity | Lamivudine
Item
patients who have not experienced viral breakthrough at consecutive two measurements (at least one month apart) during lamivudine monotherapy
boolean
C4053869 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0242485 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,4])
C0209738 (UMLS CUI [2])
Informed Consent | Protocol Compliance
Item
patients who can submit the written consent and comply with the claims postulated of this clinical trial
boolean
C0021430 (UMLS CUI [1])
C0525058 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Antiviral Therapy | Exception Lamivudine | Exception Steroid therapy
Item
currently receiving antiviral except lmv or corticosteroid therapy
boolean
C0280274 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0209738 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0149783 (UMLS CUI [3,2])
Antiviral Therapy Hepatitis B | Exception Lamivudine
Item
patients that previously received antiviral treatment for hepatitis b other than lamivudine in the proceeding 12 months
boolean
C0280274 (UMLS CUI [1,1])
C0019163 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0209738 (UMLS CUI [2,2])
Interferon To be stopped | Immunomodulation To be stopped
Item
previous treatment with interferon or other immunomodulatory therapies must have ended at least 6 months preceding the study screening
boolean
C3652465 (UMLS CUI [1,1])
C1272691 (UMLS CUI [1,2])
C1963758 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
Pharmaceutical Preparations Nephrotoxic | Pharmaceutical Preparations Hepatotoxicity
Item
treatment with nephrotoxic drugs, competitors of renal excretion, and/or hepatotoxic drugs within 2 months before study screening or during the study period
boolean
C0013227 (UMLS CUI [1,1])
C1514118 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C0235378 (UMLS CUI [2,2])
HCV coinfection | HDV Coinfection | HIV coinfection
Item
patients who is co-infected with hcv, hdv or hiv
boolean
C1698259 (UMLS CUI [1])
C0011220 (UMLS CUI [2,1])
C0275524 (UMLS CUI [2,2])
C4062778 (UMLS CUI [3])
Other medical condition Serious
Item
serious concurrent medical conditions
boolean
C3843040 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
Organ Transplantation
Item
prior organ transplantation
boolean
C0029216 (UMLS CUI [1])
Estimation of creatinine clearance by Cockcroft-Gault formula
Item
patient has creatinine clearance less than 60ml/min as estimated by the following formula:
boolean
C2711451 (UMLS CUI [1])
Estimation of creatinine clearance by Cockcroft-Gault formula | Gender
Item
[(140-age in years) (body weight [kg])] / [(72) (serum creatinine] [mg/dl])[note: multiply estimates by 0.85 for women]
boolean
C2711451 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial